Pub Date : 2024-07-01Epub Date: 2021-08-24DOI: 10.1007/s12291-021-00999-6
Farzane Amirmahani, Nasim Ebrahimi, Rafee Habib Askandar, Marzieh Rasouli Eshkaftaki, Katayoun Fazeli, Michael R Hamblin
Prostate cancer (PCa) is the second most common cancer in men throughout the world, and the main cause of cancer death. Long noncoding RNAs (lncRNAs) act as crucial regulators in many human cancers. In this research, we measured the expression level of novel lncRNAs and their associated micro-RNAs (miRNAs) in PCa. In the present research, three lncRNAs were selected using the Mitranscriptome projec (CAT2064, CAT2042, and CAT2164.2). Samples of prostate tissue (20 PCa, and 20 BPH) and blood (14 PCa, and 14 BPH) were collected and the Real-time Quantitative Polymerase Chain Reaction (RT-qPCR) was used to measure the expression levels of the lncRNAs and their associated miRNAs. Based on our results, CAT2064 was significantly increased and CAT2042 was significantly decreased in human PCa tissue in comparison with BPH tissue. To discriminate PCa from BPH, CAT2064 (P < 0.05; 0.8750 AUC-ROC) showed a better potential as a diagnostic molecular biomarker compared to CAT2042 (P < 0.05; 0.8454 AUC-ROC). Furthermore, RT-qPCR results measured in blood samples from PCa patients showed a higher expression level of CAT2064 (P < 0.0001; AUC-ROC value of 0.8914) in comparison to CAT2042. CAT2064 and CAT2042 showed a positive correlation with the expression of miR-5095 and miR-1273a (r = 0.02885, 0.3202; P = 0.9413, 0.2266, respectively). CAT2064 and CAT2042 also had a negative correlation with miR-1304-3p and miR-1285-5p (r = - 0.3877, - 0.09330; P = 0.15, 0.7311, respectively). Collectively, CAT2064 and CAT2042 and their miRNA targets may constitute a regulatory network in PCa, and could serve as novel biomarkers.
Supplementary information: The online version contains supplementary material available at 10.1007/s12291-021-00999-6.
前列腺癌（PCa）是全球第二大男性常见癌症，也是导致癌症死亡的主要原因。长非编码 RNA（lncRNA）是许多人类癌症的关键调控因子。在这项研究中，我们测量了新型lncRNA及其相关微RNA（miRNA）在PCa中的表达水平。本研究利用 Mitranscriptome projec 选定了三个 lncRNA（CAT2064、CAT2042 和 CAT2164.2）。研究人员采集了前列腺组织样本（20 个 PCa 和 20 个 BPH）和血液样本（14 个 PCa 和 14 个 BPH），并使用实时定量聚合酶链式反应（RT-qPCR）测定了这些 lncRNAs 及其相关 miRNAs 的表达水平。结果显示，与良性前列腺增生组织相比，CAT2064在人PCa组织中明显升高，而CAT2042则明显降低。为了区分 PCa 和良性前列腺增生，CAT2064（P P P P = 0.9413，0.2266，分别）和 CAT2042（P P P = 0.9413，0.2266，分别）都明显增加。CAT2064 和 CAT2042 还与 miR-1304-3p 和 miR-1285-5p 呈负相关（r = - 0.3877，- 0.09330；P = 0.15，0.7311）。总之，CAT2064和CAT2042及其miRNA靶标可能构成了PCa的调控网络，并可作为新型生物标志物：在线版本包含补充材料，见 10.1007/s12291-021-00999-6。
{"title":"Long Noncoding RNAs CAT2064 and CAT2042 may Function as Diagnostic Biomarkers for Prostate Cancer by Affecting Target MicrorRNAs.","authors":"Farzane Amirmahani, Nasim Ebrahimi, Rafee Habib Askandar, Marzieh Rasouli Eshkaftaki, Katayoun Fazeli, Michael R Hamblin","doi":"10.1007/s12291-021-00999-6","DOIUrl":"10.1007/s12291-021-00999-6","url":null,"abstract":"<p><p>Prostate cancer (PCa) is the second most common cancer in men throughout the world, and the main cause of cancer death. Long noncoding RNAs (lncRNAs) act as crucial regulators in many human cancers. In this research, we measured the expression level of novel lncRNAs and their associated micro-RNAs (miRNAs) in PCa. In the present research, three lncRNAs were selected using the Mitranscriptome projec (CAT2064, CAT2042, and CAT2164.2). Samples of prostate tissue (20 PCa, and 20 BPH) and blood (14 PCa, and 14 BPH) were collected and the Real-time Quantitative Polymerase Chain Reaction (RT-qPCR) was used to measure the expression levels of the lncRNAs and their associated miRNAs. Based on our results, CAT2064 was significantly increased and CAT2042 was significantly decreased in human PCa tissue in comparison with BPH tissue. To discriminate PCa from BPH, CAT2064 (<i>P</i> < 0.05; 0.8750 AUC-ROC) showed a better potential as a diagnostic molecular biomarker compared to CAT2042 (<i>P</i> < 0.05; 0.8454 AUC-ROC). Furthermore, RT-qPCR results measured in blood samples from PCa patients showed a higher expression level of CAT2064 (<i>P</i> < 0.0001; AUC-ROC value of 0.8914) in comparison to CAT2042. CAT2064 and CAT2042 showed a positive correlation with the expression of miR-5095 and miR-1273a (r = 0.02885, 0.3202; <i>P</i> = 0.9413, 0.2266, respectively). CAT2064 and CAT2042 also had a negative correlation with miR-1304-3p and miR-1285-5p (r = - 0.3877, - 0.09330; <i>P</i> = 0.15, 0.7311, respectively). Collectively, CAT2064 and CAT2042 and their miRNA targets may constitute a regulatory network in PCa, and could serve as novel biomarkers.</p><p><strong>Supplementary information: </strong>The online version contains supplementary material available at 10.1007/s12291-021-00999-6.</p>","PeriodicalId":15087,"journal":{"name":"Journal of Biomolecular Screening","volume":"6 1","pages":"322-330"},"PeriodicalIF":0.0,"publicationDate":"2024-07-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11239640/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"87379283","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Pub Date : 2016-12-01DOI: 10.1177/1087057116679994
N. Scharf, V. Molodtsov, A. Kontos, K. Murakami, G. Garcia
Rifampin has been a cornerstone of tuberculosis (TB) treatment since its introduction. The rise of multidrug-resistant and extensively drug-resistant TB makes the development of novel therapeutics effective against these strains an urgent need. Site-specific mutations in the target enzyme of rifampin, RNA polymerase (RNAP) comprises the majority (~97%) of rifamycin-resistant (RifR) strains of Mycobacterium tuberculosis (MTB). To identify novel inhibitors of bacterial RNAP, an in vitro plasmid-based transcription assay that uses malachite green (MG) to detect transcribed RNA containing MG aptamers was developed. This assay was optimized in a 384-well plate format and used to screen 150,000 compounds against an Escherichia coli homolog of the most clinically relevant RifR RNAP (βS531L) containing a mutation (β'V408G) that compensates for the fitness defect of this RifR mutant. Following confirmation and concentration-response studies, 10 compounds were identified with similar in vitro inhibition values across a panel of wild-type and RifR E. coli and MTB RNAPs. Four compounds identified from the screen are active against MTB in culture at concentrations below 200 µM. Initial follow-up has resulted in the elimination of one scaffold due to potential pan-assay interference.
{"title":"Novel Chemical Scaffolds for Inhibition of Rifamycin-Resistant RNA Polymerase Discovered from High-Throughput Screening.","authors":"N. Scharf, V. Molodtsov, A. Kontos, K. Murakami, G. Garcia","doi":"10.1177/1087057116679994","DOIUrl":"https://doi.org/10.1177/1087057116679994","url":null,"abstract":"Rifampin has been a cornerstone of tuberculosis (TB) treatment since its introduction. The rise of multidrug-resistant and extensively drug-resistant TB makes the development of novel therapeutics effective against these strains an urgent need. Site-specific mutations in the target enzyme of rifampin, RNA polymerase (RNAP) comprises the majority (~97%) of rifamycin-resistant (RifR) strains of Mycobacterium tuberculosis (MTB). To identify novel inhibitors of bacterial RNAP, an in vitro plasmid-based transcription assay that uses malachite green (MG) to detect transcribed RNA containing MG aptamers was developed. This assay was optimized in a 384-well plate format and used to screen 150,000 compounds against an Escherichia coli homolog of the most clinically relevant RifR RNAP (βS531L) containing a mutation (β'V408G) that compensates for the fitness defect of this RifR mutant. Following confirmation and concentration-response studies, 10 compounds were identified with similar in vitro inhibition values across a panel of wild-type and RifR E. coli and MTB RNAPs. Four compounds identified from the screen are active against MTB in culture at concentrations below 200 µM. Initial follow-up has resulted in the elimination of one scaffold due to potential pan-assay interference.","PeriodicalId":15087,"journal":{"name":"Journal of Biomolecular Screening","volume":"1 1","pages":"1087057116679994"},"PeriodicalIF":0.0,"publicationDate":"2016-12-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://sci-hub-pdf.com/10.1177/1087057116679994","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"65313127","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Pub Date : 2008-10-01DOI: 10.1177/10870571080130091501
Cellectricon has introduced the Cellaxess®HT System, an automated system for reagent-free transfection that enables reagent-free delivery of siRNA and cDNA to host cells at a throughput of 50,000 wells per day. The system uses capillary electrode arrays for reagent-free transfection of cells directly in 384-well plates. The plates are designed for high-content screening (HCS) readout and are compatible with
{"title":"Product Focus","authors":"","doi":"10.1177/10870571080130091501","DOIUrl":"https://doi.org/10.1177/10870571080130091501","url":null,"abstract":"Cellectricon has introduced the Cellaxess®HT System, an automated system for reagent-free transfection that enables reagent-free delivery of siRNA and cDNA to host cells at a throughput of 50,000 wells per day. The system uses capillary electrode arrays for reagent-free transfection of cells directly in 384-well plates. The plates are designed for high-content screening (HCS) readout and are compatible with","PeriodicalId":15087,"journal":{"name":"Journal of Biomolecular Screening","volume":"13 1","pages":"922 - 927"},"PeriodicalIF":0.0,"publicationDate":"2008-10-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://sci-hub-pdf.com/10.1177/10870571080130091501","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"65310843","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Pub Date : 2008-09-01DOI: 10.1177/10870571080130081201
BioTek Instruments, Inc. announced a new software tool for clinical laboratories using its ELx800 and ELx808 microplate readers. The data collection and analysis software offer preprogrammed clinical diagnostic assays in a PC-based application. The PC-based interface provides flexibility in data analysis and output options and includes LIS system compatibility and data/protocol storage. In addition,
{"title":"Product Focus","authors":"","doi":"10.1177/10870571080130081201","DOIUrl":"https://doi.org/10.1177/10870571080130081201","url":null,"abstract":"BioTek Instruments, Inc. announced a new software tool for clinical laboratories using its ELx800 and ELx808 microplate readers. The data collection and analysis software offer preprogrammed clinical diagnostic assays in a PC-based application. The PC-based interface provides flexibility in data analysis and output options and includes LIS system compatibility and data/protocol storage. In addition,","PeriodicalId":15087,"journal":{"name":"Journal of Biomolecular Screening","volume":"13 1","pages":"822 - 826"},"PeriodicalIF":0.0,"publicationDate":"2008-09-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://sci-hub-pdf.com/10.1177/10870571080130081201","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"65310782","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Pub Date : 2008-07-01DOI: 10.1177/10870571080130061201
BioTek Instruments has announced the Synergy 4 multidetection microplate reader, which combines a fluorescence filter-based detection system and a monochromator-based detection system in 1 unit. The filter-based system can be used when high sensitivity or fast read speeds are a requirement. The monochromator system is available when spectral scanning is needed. This modular reader can be ordered fully loaded with all measurement modes or customized to fit budgetary requirements with the option to add other detection technologies at a later date. Available options include filterbased and monochromator-based fluorescence intensity, time-resolved fluorescence, fluorescence polarization, UV-visible absorbance, flash and glow luminescence, and a dual-reagent
{"title":"Product Focus: Screening Robotics and Automation","authors":"","doi":"10.1177/10870571080130061201","DOIUrl":"https://doi.org/10.1177/10870571080130061201","url":null,"abstract":"BioTek Instruments has announced the Synergy 4 multidetection microplate reader, which combines a fluorescence filter-based detection system and a monochromator-based detection system in 1 unit. The filter-based system can be used when high sensitivity or fast read speeds are a requirement. The monochromator system is available when spectral scanning is needed. This modular reader can be ordered fully loaded with all measurement modes or customized to fit budgetary requirements with the option to add other detection technologies at a later date. Available options include filterbased and monochromator-based fluorescence intensity, time-resolved fluorescence, fluorescence polarization, UV-visible absorbance, flash and glow luminescence, and a dual-reagent","PeriodicalId":15087,"journal":{"name":"Journal of Biomolecular Screening","volume":"13 1","pages":"544 - 548"},"PeriodicalIF":0.0,"publicationDate":"2008-07-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://sci-hub-pdf.com/10.1177/10870571080130061201","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"65310718","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Pub Date : 2008-06-01DOI: 10.1177/1087057108317441
T. Chung
{"title":"Book Review: Immunoassay and Other Bioanalytical Techniques, edited by Jeanette M. Van Emon. Boca Raton, FL: CRC Press, Taylor & Francis Group; 2007. 512 pp. Hardcover. ISBN 10:0—8493—3942—1","authors":"T. Chung","doi":"10.1177/1087057108317441","DOIUrl":"https://doi.org/10.1177/1087057108317441","url":null,"abstract":"","PeriodicalId":15087,"journal":{"name":"Journal of Biomolecular Screening","volume":"29 1","pages":"430 - 431"},"PeriodicalIF":0.0,"publicationDate":"2008-06-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://sci-hub-pdf.com/10.1177/1087057108317441","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"65310693","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Pub Date : 2008-03-01DOI: 10.1177/10870571080130030901
Guava Technologies Inc. has introduced a new generation of software for its Guava EasyCyteTM Plus microcapillary flow cytometry system. Designed for both data acquisition and analysis, the software interface allows you to visualize up to 8 plots simultaneously while still accessing operation or data analysis functions. With a right click of the mouse, features including the plot type, marker selection, statistics, gates, and other functions can be customized to your experimental design. Color-coded dots allow you to follow your gating strategies across multiple plots and
{"title":"Product Focus: Software, Databases, and Information Services","authors":"","doi":"10.1177/10870571080130030901","DOIUrl":"https://doi.org/10.1177/10870571080130030901","url":null,"abstract":"Guava Technologies Inc. has introduced a new generation of software for its Guava EasyCyteTM Plus microcapillary flow cytometry system. Designed for both data acquisition and analysis, the software interface allows you to visualize up to 8 plots simultaneously while still accessing operation or data analysis functions. With a right click of the mouse, features including the plot type, marker selection, statistics, gates, and other functions can be customized to your experimental design. Color-coded dots allow you to follow your gating strategies across multiple plots and","PeriodicalId":15087,"journal":{"name":"Journal of Biomolecular Screening","volume":"13 1","pages":"246 - 248"},"PeriodicalIF":0.0,"publicationDate":"2008-03-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://sci-hub-pdf.com/10.1177/10870571080130030901","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"65310627","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
扫码关注我们
求助内容：
应助结果提醒方式：
京公网安备 11010802042870号